Phreesia (PHR) Expected to Announce Earnings on Wednesday

Phreesia (NYSE:PHR - Get Free Report) is expected to announce its Q1 2026 earnings results before the market opens on Wednesday, May 28th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $115.00 million for the quarter.

Phreesia Stock Performance

Shares of Phreesia stock traded down $0.27 during trading on Monday, reaching $24.07. The company's stock had a trading volume of 242,602 shares, compared to its average volume of 439,105. The company has a 50-day moving average price of $25.08 and a two-hundred day moving average price of $25.24. Phreesia has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The firm has a market cap of $1.43 billion, a PE ratio of -16.37 and a beta of 0.74. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PHR shares. Needham & Company LLC restated a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Wall Street Zen cut Phreesia from a "buy" rating to a "hold" rating in a research report on Saturday. KeyCorp reduced their price objective on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Wednesday, April 16th. Canaccord Genuity Group increased their price objective on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Finally, Piper Sandler reissued an "overweight" rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $31.33.

Insider Transactions at Phreesia

In other news, SVP David Linetsky sold 4,499 shares of the company's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.73, for a total transaction of $106,761.27. Following the transaction, the senior vice president now directly owns 217,239 shares of the company's stock, valued at $5,155,081.47. This represents a 2.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Yvonne Hui sold 1,878 shares of the firm's stock in a transaction dated Tuesday, April 8th. The shares were sold at an average price of $23.85, for a total transaction of $44,790.30. Following the completion of the sale, the insider now owns 28,449 shares of the company's stock, valued at $678,508.65. This trade represents a 6.19% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 42,474 shares of company stock valued at $1,023,208. Corporate insiders own 5.80% of the company's stock.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Phreesia by 3.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company's stock worth $1,599,000 after acquiring an additional 2,158 shares during the period. Goldman Sachs Group Inc. boosted its position in Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company's stock worth $15,336,000 after purchasing an additional 2,402 shares in the last quarter. NewEdge Advisors LLC boosted its position in Phreesia by 262.7% during the first quarter. NewEdge Advisors LLC now owns 15,437 shares of the company's stock worth $395,000 after purchasing an additional 11,181 shares in the last quarter. Caxton Associates LLP acquired a new stake in Phreesia in the first quarter valued at $316,000. Finally, Royal Bank of Canada increased its position in shares of Phreesia by 208.8% in the first quarter. Royal Bank of Canada now owns 24,119 shares of the company's stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.